Hong Kong Stock Market Midday Review | Hang Seng Index Down 0.43%, Hang Seng Biotech Index Up 1.77%

We have learned from Zhixin Financial App that the Hong Kong stock market's Hang Seng Index fell by 0.43% or 109 points, while the Hang Seng Biotech Index rose by 1.77%. The early trading volume reached HK$14.82 billion.

The Hang Seng Biotech Index went against the trend and rose by 1.77%. Micronova Medical (00853) rose by 9.7%; Micronova Brain Sciences (02172) rose over 8%; and SinDa Bio (01801) rose by 4.85%.

The pharmaceutical sector continued to rise, with Yongmei Konde (02359) rising by 2.24%, Yongmei Jinyu-B (02126) rising by 6.5%, and Yongmei Bio (02269) again rising over 3%. The company announced the launch of its modularized biopharmaceutical production facility in Singapore.

Chuangxun Pharmaceutical (02196) rose over 5%, with the company acquiring the exclusive license for AR1001, an innovative Alzheimer's disease treatment developed by New York-based Nuvo Pharmaceuticals.

Healthcare stocks continued to rise, with Xin Hua Insurance (01336) rising by 4.47% and China Life Insurance (02628) rising by 1.5%.

361 Degrees (01361) rose by 6.5%, with the company's revenue growth remaining stable and institutional analysts predicting a strong confirmation of its full-year income growth.

Zhilian Dreamland (01119) again rose by 3.5%, after signing a capitalization agreement with Playrix, introducing a long-term cooperative upstream developer as a strategic shareholder.

Jiakaosi-B (01167) rose over 20%, with one shareholder increasing their stake to over 6,000 shares, with the latest holding reaching 25.36%.

Semiconductor stocks collectively fell, with NVIDIA's order for 300,000 H20 chips causing a market sentiment impact. Wah Hong Semiconductor (01347) fell by 5.3%, SMIC International (00981) fell by 3.9%, and ASMPT (00522) fell by 2.74%.